Physician profile
David B Feldman
NPI 1306817440
$2,715.25
in general payments reported to CMS, 2019-2025
24 companies · $143 in 2025
The $143 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,264 · 2020: $178 · 2021: $59.73 · 2022: $383 · 2023: $293 · 2024: $394 · 2025: $143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $830.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $829.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $421.89 | 2021-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $239.85 | 2019-2024 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $235.04 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $195.84 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $188.10 | 2019-2020 | |
| Alkermes, INC. | $186.76 | 2019-2025 | Aristada, Lybalvi |
| Vanda Pharmaceuticals INC. | $165.26 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $121.29 | 2022 | |
| Axsome Therapeutics, INC. | $121.28 | 2023 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $119.42 | 2024 | Cobenfy |
| Lundbeck LLC | $104.99 | 2019 | |
| Shire North American Group INC | $96.20 | 2019 | |
| Abbvie INC. | $91.56 | 2021-2023 | |
| Sunovion Pharmaceuticals INC. | $81.79 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $81.06 | 2019-2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $53.55 | 2019 | |
| Neos Therapeutics, LP | $43.15 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $42.05 | 2019 | |
| Jazz Pharmaceuticals INC. | $40.01 | 2019-2020 | |
| Allergan, INC. | $24.57 | 2019 | |
| Validus Pharmaceuticals LLC | $21.71 | 2019-2020 | |
| Adlon Therapeutics L.P. | $15.92 | 2019 | |
| Arbor Pharmaceuticals, INC. | $12.17 | 2019 | |
| Livanova USA, INC. | $11.79 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Feldman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.